India-based pharmaceutical company Dr Reddy’s Laboratories has realigned its global generics finished dosages strategy to focus on certain key geographies and would gradually exit some of the very small distributor driven markets.
In addition to the US, India, Russia & CIS and Germany where the operations are already very large contributing to approximately 90% of the global generics revenues, the company will continue operations in 10-15 markets wherein the company’s finished dosages sales are growing significantly, said Dr Reddy’s.
This move represents an important new focus in the global generics business to consolidate and grow the company’s presence in the key geographies where it already has a considerable presence. The exercise would result in reduction of complexity of operations on one hand and help in significantly enhanced customer service and market share on the other, the company said.
Satish Reddy, COO of Dr Reddy’s, said: We intend to aggressively step up our presence in our key markets with this strategic prioritization. The market prioritization exercise would lead to redeployment of resources within the organization. The company will however continue to scan opportunities and attractiveness of international markets in line with its business strategy.